The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Open accessAbstract
Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Ki67 in Breast Cancer Working Group (IKWG) consensus meeting, held in October 2019, assessed the current evidence for Ki67 IHC analytical validity and clinical utility in breast cancer, including the series of scoring studies the IKWG conducted on centrally stained tissues. Consensus observations and recommendations are: 1) as for estrogen receptor and HER2 testing, preanalytical handling considerations are critical; 2) a standardized visual scoring method has been established and is recommended for adoption; 3) participation in and evaluation of quality assurance and quality control programs is recommended to maintain analytical validity; and 4) the IKWG accepted that Ki67 IHC as a prognostic marker in breast cancer has clinical validity but concluded that clinical utility is evident only for prognosis estimation in anatomically favorable estrogen receptor–positive and HER2-negative patients to identify those who do not need adjuvant chemotherapy. In this T1-2, N0-1 patient group, the IKWG consensus is that Ki67 5% or less, or 30% or more, can be used to estimate prognosis. In conclusion, analytical validity of Ki67 IHC can be reached with careful attention to preanalytical issues and calibrated standardized visual scoring. Currently, clinical utility of Ki67 IHC in breast cancer care remains limited to prognosis assessment in stage I or II breast cancer. Further development of automated scoring might help to overcome some current limitations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U., & Stein, H. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1710 · Cited by 4,173
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
Self-citationEarly Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Self-citationEstrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574
Self-citationThe real-time polymerase chain reaction
Kubista, M., Andrade, J. M., Bengtsson, M., Forootan, A., Jonák, J., Lind, K., Sindelka, R., Sjöback, R., Sjögreen, B., Strömbom, L., et al. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.12.007 · Cited by 1,515
Ki67 in breast cancer: prognostic and predictive potential
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., & Gelmon, K. A. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70262-1 · Cited by 1,207
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.907 · Cited by 895
Self-citationBast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Self-citationHarris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Self-citationCuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739
Self-citationSymmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., Walls, A., Bousamra, A., Ramineni, M., Sinn, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1010 · Cited by 711
Teutsch, S. M., Bradley, L. A., Palomaki, G. E., Haddow, J. E., Piper, M., Calonge, N., Dotson, W. D., Douglas, M. P., & Berg, A. O. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e318184137c · Cited by 680
Eighth edition of the AJCC cancer staging manual: breast cancer
Giuliano, A. E., Edge, S. B., & Hortobagyi, G. N. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6486-6 · Cited by 678
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., A'Hern, R., Salter, J., Detre, S., Hills, M., & Walsh, G. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djk020 · Cited by 665
Self-citationEllis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Self-citationHER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
Self-citationInwald, E. C., Klinkhammer-Schalke, M., Hofstädter, F., Zeman, F., Koller, M., Gerstenhauer, M., & Ortmann, O. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2560-8 · Cited by 601
An International Ki67 Reproducibility Study
Polley, M.-Y. C., Leung, S. C. Y., McShane, L. M., Gao, D., Hugh, J. C., Mastropasqua, M. G., Viale, G., Zabaglo, L. A., Penault-Llorca, F., Bartlett, J. M. S., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt306 · Cited by 595
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., et al. (2010) · PubMed Central · Cited by 541
Self-citationSauerbrei, W., Taube, S. E., McShane, L. M., Cavenagh, M. M., & Altman, D. G. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy088 · Cited by 486
Self-citationFehrenbacher, L., Cecchini, R. S., Geyer Jr, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J.-F., Provencher, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01455 · Cited by 404
Ellis, M. J., Suman, V. J., Hoog, J., Goncalves, R., Sanati, S., Creighton, C. J., DeSchryver, K., Crouch, E., Brink, A., Watson, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.4406 · Cited by 366
Self-citationMa, C. X., Gao, F., Luo, J., Northfelt, D. W., Goetz, M., Forero, A., Hoog, J., Naughton, M., Ademuyiwa, F., Suresh, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3206 · Cited by 366
Self-citationColleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., Gelber, R. D., Curigliano, G., Torrisi, R., Luini, A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0380 · Cited by 353
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2843 · Cited by 353
Dowsett, M., Smith, I. E., Ebbs, S. R., Dixon, J. M., Skene, A., Griffith, C., Boeddinghaus, I., Salter, J., Detre, S., Hills, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.951s.11.2 · Cited by 348
Self-citationThe prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Jones, R. L., Salter, J., A’Hern, R., Nerurkar, A., Parton, M., Reis-Filho, J. S., Smith, I. E., & Dowsett, M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0081-7 · Cited by 321
Self-citationKrop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., Hammond, M. E., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.0472 · Cited by 315
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2008) · The Lancet · doi:10.1016/s0140-6736(08)60069-0 · Cited by 279
Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer
Penault-Llorca, F., André, F., Sagan, C., Lacroix-Triki, M., Denoux, Y., Verriele, V., Jacquemier, J., Baranzelli, M. C., Bibeau, F., Antoine, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2808 · Cited by 243
Self-citationJohnston, S., Puhalla, S., Wheatley, D., Ring, A., Barry, P., Holcombe, C., Boileau, J. F., Provencher, L., Robidoux, A., Rimawi, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01624 · Cited by 228
Self-citationHurvitz, S. A., Martin, M., Press, M. F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer, R., Guarneri, V., Huang, C.-S., Barriga, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1425 · Cited by 227
Varga, Z., Diebold, J., Dommann-Scherrer, C., Frick, H., Kaup, D., Noske, A., Obermann, E., Ohlschlegel, C., Padberg, B., Rakozy, C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037379 · Cited by 226
Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Visvanathan, K., Fabian, C. J., Bantug, E., Brewster, A. M., Davidson, N. E., DeCensi, A., Floyd, J. D., Garber, J. E., Hofstatter, E. W., Khan, S. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01472 · Cited by 218
An international study to increase concordance in Ki67 scoring
Polley, M.-Y. C., Leung, S. C. Y., Gao, D., Mastropasqua, M. G., Zabaglo, L. A., Bartlett, J. M. S., McShane, L. M., Enos, R. A., Badve, S. S., Bane, A. L., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.38 · Cited by 214
Self-citationMengel, M., von Wasielewski, R., Wiese, B., Rüdiger, T., Müller‐Hermelink, H. K., & Kreipe, H. (2002) · The Journal of Pathology · doi:10.1002/path.1218 · Cited by 213
Self-citationHER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations
Carlson, R. W., Moench, S. J., Hammond, M. E. H., Perez, E. A., Burstein, H. J., Allred, D. C., Vogel, C. L., Goldstein, L. J., Somlo, G., Gradishar, W. J., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2003 · Cited by 205
Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
McShane, L. M., & Hayes, D. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6858 · Cited by 185
Self-citationKi67 reproducibility using digital image analysis: an inter-platform and inter-operator study
Ács, B., Pelekanou, V., Bai, Y., Martínez-Morilla, S., Toki, M. I., Leung, S. C. Y., Nielsen, T. O., & Rimm, D. L. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0123-7 · Cited by 154
Self-citationLeung, S. C. Y., Nielsen, T. O., Zabaglo, L. A., Arun, I., Badve, S., Bane, A. L., Bartlett, J. M. S., Borgquist, S., Chang, M. C., Dodson, A. R., et al. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.14 · Cited by 153
Self-citationNeoadjuvant treatments for triple-negative breast cancer (TNBC)
von Minckwitz, G., & Martín, M. (2012) · Annals of Oncology · doi:10.1093/annonc/mds193 · Cited by 149
Biospecimen Reporting for Improved Study Quality
Moore, H. M. (2011) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 145
Goldstein, L. J., Perez, R. P., Yardley, D. A., Han, L. K., Reuben, J. M., Gao, H., McCanna, S., Butler, B., Ruffini, P. A., Liu, Y., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-019-1243-8 · Cited by 135
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy
Sheri, A., Smith, I. E., Johnston, S. R. D., A’Hern, R., Nerurkar, A. Y., Jones, R. L., Hills, M., DETRE, S. I., Pinder, S. E., Symmans, W. F., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu508 · Cited by 125
Self-citationBuus, R., Šestak, I., Kronenwett, R., Ferree, S., Schnabel, C. A., Baehner, F. L., Mallon, E., Cuzick, J. M., & Dowsett, M. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00853 · Cited by 122
Self-citationHofmann, D., Nitz, U. A., Gluz, O., et al. (2013) · Trials · doi:10.1186/1745-6215-14-261 · Cited by 115
Lippman, M. E., & Allegra, J. C. (1978) · New England Journal of Medicine · doi:10.1056/nejm197810262991706 · Cited by 103
Klauschen, F., Wienert, S., Schmitt, W., Loibl, S., Gerber, B., Blohmer, J., Huober, J., Rüdiger, T., Erbstößer, E., Mehta, K. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1283 · Cited by 103
Self-citationRimm, D. L., Leung, S. C. Y., McShane, L. M., Bai, Y., Bane, A. L., Bartlett, J. M. S., Bayani, J., Chang, M. C., Dean, M. L., Denkert, C., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0109-4 · Cited by 99
Self-citationArnaout, A., Robertson, S. J., Pond, G. R., Lee, H., Jeong, A., Ianni, L., Kroeger, L., Hilton, J. F., Coupland, S. G., Gottlieb, C., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05381-y · Cited by 82
Assersohn, L., Salter, J., Powles, T. J., A’Hern, R., Makris, A., Gregory, R. K., Chang, J. C., & Dowsett, M. (2003) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000003968.45511.3f · Cited by 69
Self-citationMikami, Y., Ueno, T., Yoshimura, K., et al. (2013) · Cancer Science · doi:10.1111/cas.12245 · Cited by 68
Muftah, A. A., Aleskandarany, M. A., Al-kaabi, M. M., Sonbul, S. N., Diez, M., Nolan, C. C., Caldas, C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4270-0 · Cited by 63
Gluz, O., Kolberg‐Liedtke, C., Prat, A., Christgen, M., Gebauer, D., Kates, R. E., Paré, L., Grischke, E., Forstbauer, H., Braun, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32488 · Cited by 50
Self-citationA novel model for Ki67 assessment in breast cancer
Romero, Q., Bendahl, P., Fernö, M., Grabau, D. A., & Borgquist, S. (2014) · Diagnostic Pathology · doi:10.1186/1746-1596-9-118 · Cited by 44
Lænkholm, A., Grabau, D. A., Talman, M., Balslev, E., Jylling, A. M. B., Tabor, T. P., Johansen, M. M., Brügmann, A. H., Lelkaitis, G., Caterino, T. D., et al. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1404127 · Cited by 44
Martin, L., Davies, G., Weigel, M. T., Betambeau, N., Hills, M. J., Salter, J., Walsh, G., A’Hern, R., & Dowsett, M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1100-z · Cited by 43
Self-citationPfitzner, B. M., Lederer, B., Lindner, J., Solbach, C., Engels, K., Rezai, M., Dohnal, K., Tesch, H., Hansmann, M. L., Salat, C., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.171 · Cited by 37
Self-citationSteady Progress against HER2-Positive Breast Cancer
Hayes, D. F. (2011) · New England Journal of Medicine · doi:10.1056/nejme1101326 · Cited by 14
Self-citationAyad, E., Soliman, A., Anis, S. E., Salem, A. B., Hu, P., & Dong, Y. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0735-7 · Cited by 9
Cited by
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Self-citationAndre, F., Ismaila, N., Allison, K. H., Barlow, W. E., Collyar, D. E., Damodaran, S., Henry, N. L., Jhaveri, K., Kalinsky, K., Kuderer, N. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00069 · Cited by 365
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
Davey, M. G., Hynes, S. O., Kerin, M. J., Miller, N., & Lowery, A. J. (2021) · Cancers · doi:10.3390/cancers13174455 · Cited by 298
Poirier, A., Gagné, A., Laflamme, P., Marcoux, M., Orain, M., Plante, S., Joubert, D., Joubert, P., & Laplante, M. (2021) · Cancers · doi:10.3390/cancers13164136 · Cited by 15
Metadata
- Authors
- Nielsen, T. O., Leung, S. C. Y., Rimm, D. L., Dodson, A., Acs, B., Badve, S., Denkert, C., Ellis, M. J., Fineberg, S., Flowers, M., Kreipe, H. H., Laenkholm, A.-V., Pan, H., Penault-Llorca, F. M., Polley, M.-Y., Salgado, R., Smith, I. E., Sugie, T., Bartlett, J. M. S., McShane, L. M., Dowsett, M., & Hayes, D. F.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-28
- Volume
- 113
- Issue
- 7
- Pages
- 808-819
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W4213418594
- Cited by
- 753
- References
- 66
- FWCI
- 23.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.